

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

All items marked with an * are mandatory to complete
The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name- Sentaur Bio * Website- www.sentaurbio.com *

CEO name- Dganit Bar *

Select a CATEGORY: **Biotech**/Pharma or Medical Devices or Health IT/Digital *
(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

1. **Longevity - How to Complete the Centenarian Decathlon?**
2. Do we Know Enough About the Brain to Treat Neurological Disorders?
3. Are Cancer Therapeutics Fulfilling the Promise?
4. Can we Successfully Diagnose and Guide Patients' Optimal Cancer Treatment?
5. AI tapestry: optimizing the interaction of AI and Biopharma
6. Facts and Myths on Ex-Liver Delivery of Nucleic Acid Therapeutics
7. Patients are Consumers at Home – How Far Can They Manage Their Health?
8. Robots Dancing with Humans in the Healthcare Systems and Homes
9. Are Medical Devices Still Relevant in the Context of New Biology?
10. Let food be thy medicine and medicine be thy food
11. How do we make Academic Translation Medicine replicable and relevant?
12. Bio Convergence - Everything That Rises Must Converge.
13. Skin health and Beauty

You may delete the section instructions, leaving **only the bolded bullet title**
Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational**
Sentaur Bio is an early-stage biotech company harnessing senescence biology to develop targeted therapies for multiple age-related diseases with a current focus on oncology. Sentaur is an M Ventures-backed company, founded in 2019 based on IP licensed from the laboratory of Prof. Valery Krizhanovsky from the Weizmann Institute of Science.
- **Core Technology**
Sentaur's discovery engine platform uses high throughput proteomic analysis to identify senescent cells surface proteins and develop therapeutics specifically targeting disease specific senescent cells.
- **Product Profile/Pipeline**
Sentaur is currently developing two highly distinct antibody candidates that target disease relevant senescent cells. The company's lead asset, SB101 is an antibody drug

conjugate (ADC) with a dual effect on senescent and tumor cells. Our second candidate SB201 is an intracellular protein described for the first time to be localized on the cell surface.

- **Business Strategy**

Sentaur plans to advance our two antibody candidates to substantial inflection points as well as strengthen our platform and IP portfolio for strategic partnerships.

- **What's Next?**

Upon completion of pre-clinical proof of concept studies for our lead asset SB101, Sentaur plans to perform lead optimization and proceed with pre-clinical and clinical studies. In parallel, we will continue advancing our second candidate SB201 to pre-clinical development as well as use our discovery platform to identify new targets and expand our pipeline.